GE HealthCare (GEHC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$83.75-2.40%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · GEHC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks GEHC against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”
Stated in 7 of 8 supplied quarters. Management reported: “This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations.” “With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”” Revenue was $5.513 billion in 2026-Q3.
“With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.””
“We are maintaining our topline growth guidance driven by healthy customer demand globally.”
“As we look ahead, we are committed to executing on our strategy to drive top- and bottom-line growth in 2026 and over the medium-term.””
“We continue to see momentum with commercial execution, where our teams leverage our broad portfolio and services, creating sustainable revenue and strengthening customer relationships.”
“Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.””
“GE HealthCare President and CEO Peter Arduini said, “First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength i…”
This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations.
Stated in 7 of 8 supplied quarters. Management reported: “This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations.” “Given these dynamics, we are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions.”
With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”
Stated in 7 of 8 supplied quarters. Management reported: “With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”” “While the macro environment remains dynamic, we are focused on delivering profitable growth, strong cash flow, and shareholder value.””
“With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.””
Importantly, we are making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth.”
Stated in 6 of 8 supplied quarters. Management reported: “Importantly, we are making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth.”” “We continue to prioritize investment in innovation and capacity expansion.”
“Importantly, we are making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth.””
This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.
Stated in 1 of 8 supplied quarters. Management reported: “This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.” “Following this organizational change, the Company has three reportable segments: AIS, Pharmaceutical Diagnostics (“PDx”), and Patient Care Solutions (“PCS”), which is aligned with how the Chief Operating Decision Maker reviews the business for the purpose of assessing performance and allocating resources.”
Over the trailing year it converted 1.16x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Most sensitive to the US dollar and the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.
“We remain committed to our precision care strategy for growth, supported by innovation, productivity initiatives, and commercial execution.””
“This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations.”
“Given these dynamics, we are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions.”
““We advanced Heartbeat, our proprietary business system, to improve the customer experience and drive productivity to deliver margin expansion, and greater value for patients, customers and sharehold…”
“As a result of our increased R&D investments, we are entering a new wave of innovation and, coupled with our focus on lean, we expect to accelerate top and bottom line growth.””
“Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.””
“GE HealthCare President and CEO Peter Arduini said, “First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength i…”
“We remain committed to our precision care strategy for growth, supported by innovation, productivity initiatives, and commercial execution.””
“Document Exhibit 99 GE HealthCare reports first quarter 2026 financial results • Revenue gr owth of 7.4%, including Organic revenue growth* of 2.9% • Total orders up 1.1% organically versus 10.3% gro…”
“While the macro environment remains dynamic, we are focused on delivering profitable growth, strong cash flow, and shareholder value.””
“Document Exhibit 99 GE HealthCare reports third quarter 2025 financial results • Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa…”
“Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.””
“GE HealthCare President and CEO Peter Arduini said, “First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength i…”
“We remain committed to our precision care strategy for growth, supported by innovation, productivity initiatives, and commercial execution.””
“We continue to prioritize investment in innovation and capacity expansion.”
“As a result of our increased R&D investments, we are entering a new wave of innovation and, coupled with our focus on lean, we expect to accelerate top and bottom line growth.””
“Overall, we believe we are driving long-term value through our strategic priorities and are well positioned operationally.””
“GE HealthCare President and CEO Peter Arduini said, “First quarter results reflect strong execution as we start the year with robust revenue, orders and profit growth, which were driven by strength i…”
“We remain committed to our precision care strategy for growth, supported by innovation, productivity initiatives, and commercial execution.””
“This change positions the Company to enhance execution, accelerate innovation, and create efficiencies.”